09:06 AM EDT, 07/02/2026 (MT Newswires) -- Polyrizon ( PLRZ ) said Thursday that its proprietary Nasarix nasal spray met all required biological safety standards in a biocompatibility evaluation program.

The testing followed internationally recognized standards and all key endpoints, including cytotoxicity, sensitization, irritation, and systemic toxicity, met acceptance criteria, the company said.

The completion of the program is an "important step toward potential commercialization of the product as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies," the company said.